About MLYS Dividend Returns
Mineralys Therapeutics, Inc. (MLYS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of MLYS over the past year?
Mineralys Therapeutics, Inc. (MLYS) delivered a return of 220.13% over the past year. Since MLYS does not currently pay dividends, the total return equals the price-only return.
Q2How much would $10,000 invested in MLYS be worth today?
A $10,000 investment in Mineralys Therapeutics, Inc. one year ago would be worth $32,013 today, representing a gain of $22,013.
Q3Does MLYS pay dividends?
Mineralys Therapeutics, Inc. (MLYS) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MLYS, the total return equals the price-only return.
Q4Did MLYS beat the S&P 500?
Yes, Mineralys Therapeutics, Inc. (MLYS) outperformed the S&P 500 by 204.68 percentage points over the past year. MLYS delivered a total return of 220.13%, compared to the S&P 500's 15.45%. This 204.68pp alpha means investors in MLYS earned more than a passive S&P 500 index fund.
Q5What is MLYS's worst drawdown?
Mineralys Therapeutics, Inc. (MLYS) experienced a maximum drawdown of -41.69% over the past year, declining from its peak on 2025-11-12 to its trough on 2026-02-13. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is MLYS's long-term total return over 10, 20, or 30 years?
Mineralys Therapeutics, Inc. (MLYS) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is 58.7% (4.7% CAGR) — $10,000 would have grown to $15,868. Over 20 years: 58.7% total return (2.3% CAGR) — $10,000 → $15,868. Over 30 years: 58.7% total return (1.6% CAGR) — $10,000 → $15,868. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was MLYS's best and worst year?
Mineralys Therapeutics, Inc.'s best calendar year was 2025 with a total return of 196.2%. Its worst year was 2023 with a total return of -53.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 249.6 percentage points.
Find the Best Dividend Stocks
Screen for dividend stocks with the highest total returns (including DRIP).